Tempus AI (NASDAQ:TEM) Director Sells $33,300.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $90.00, for a total transaction of $33,300.00. Following the completion of the transaction, the director owned 26,671 shares of the company’s stock, valued at approximately $2,400,390. This trade represents a 1.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Tempus AI Stock Down 2.6%

Shares of NASDAQ:TEM traded down $2.23 during trading on Wednesday, hitting $82.26. The company’s stock had a trading volume of 8,868,307 shares, compared to its average volume of 11,480,602. The business has a 50 day moving average price of $85.84 and a two-hundred day moving average price of $70.52. The company has a market capitalization of $14.29 billion, a PE ratio of -69.13 and a beta of 4.86. The company has a debt-to-equity ratio of 2.58, a quick ratio of 1.43 and a current ratio of 1.54. Tempus AI, Inc. has a fifty-two week low of $31.36 and a fifty-two week high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The company had revenue of $334.21 million during the quarter, compared to analysts’ expectations of $328.89 million. During the same quarter in the previous year, the business posted ($0.46) EPS. The firm’s revenue was up 84.7% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. As a group, research analysts expect that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

Several large investors have recently bought and sold shares of TEM. Cranbrook Wealth Management LLC acquired a new position in Tempus AI in the third quarter valued at $25,000. Concord Wealth Partners boosted its stake in Tempus AI by 308.0% in the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after acquiring an additional 308 shares in the last quarter. GAMMA Investing LLC acquired a new position in Tempus AI in the third quarter valued at $28,000. Allworth Financial LP boosted its stake in Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after acquiring an additional 450 shares in the last quarter. Finally, SouthState Corp boosted its stake in Tempus AI by 3,761.5% in the second quarter. SouthState Corp now owns 502 shares of the company’s stock valued at $32,000 after acquiring an additional 489 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on TEM. HC Wainwright boosted their target price on shares of Tempus AI from $90.00 to $98.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Canaccord Genuity Group lowered their target price on shares of Tempus AI from $110.00 to $95.00 and set a “buy” rating for the company in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a research note on Wednesday, October 8th. Morgan Stanley boosted their target price on shares of Tempus AI from $65.00 to $68.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 12th. Finally, Cowen downgraded shares of Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $80.54.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.